Yu-Ching Chang

Yu-Ching Chang

Auto-generated profile, based on publicly available information

Yu-Ching Chang

Division of Cardiology, Department of Internal Medicine and Cardiovascular Center, National Taiwan University Hospital, Taipei, Taiwan

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 March 2025 in Journal of the Formosan Medical Association
Verified
Journal Article
Open access
CLCheng-Wei Lien
Cheng-Wei Lien
YLYi-Hsuan Lee
Yi-Hsuan Lee
Chia-Wen LuChia-Wen Lu
Chia-Wen Lu
YCYu-Ching Chang
Yu-Ching Chang
YLYi-Syuan Lin
Yi-Syuan Lin
Yi-Chen LeeYi-Chen Lee
Yi-Chen Lee
Arterial hypertension is the most important modifiable risk factor for cardiovascular disease and a leading cause of death. The incidence of hypertension increases with age, with a lifetime risk of more than 90% for elderly individuals. With the growth in the absolute numbers and proportion of the elderly population worldwide, the economic impact and burden on healthcare systems due to elderly hypertension continue to rise. However, inconsistencies in the definition of elderly hypertension in different guidelines and the controversial results of various clinical trials underscore the importance of determining the consensus of management for elderly hypertension. Therefore, to clarify the current situation, this article discusses the definition, prevalence, and economic impacts of elderly hypertension.

26 January 2025 in Journal of the Formosan Medical Association
Verified
Journal Article
Open access
KWKuan-Chieh Wang
Kuan-Chieh Wang
LLLi-Chun Lin
Li-Chun Lin
SPSzu-Yu Pan
Szu-Yu Pan
JHJenq-Wen Huang
Jenq-Wen Huang
YCYu-Ching Chang
Yu-Ching Chang
BCBang-Bin Chen
Bang-Bin Chen
Contrast media are essential agents that enhance the diagnostic capabilities of imaging studies, such as computed tomography and magnetic resonance imaging. However, concerns regarding the risk of adverse events have led to cautious use in patients with chronic kidney disease. A multidisciplinary review by nephrologists, cardiologists, and radiologists at National Taiwan University Hospital examined evidence linking iodinated contrast media and gadolinium-based contrast agents with acute kidney injury and nephrogenic systemic fibrosis. The consensus is that the risk of iodinated contrast-induced acute kidney injury is minimal in patients with an estimated glomerular filtration rate greater than 30 mL/min/1.73 m2. Preventive strategies, including hydration with 0.9% saline and limiting contrast volume, may further reduce acute kidney injury risk in susceptible individuals. For nephrogenic systemic fibrosis, the risk is negligible with group II gadolinium-based contrast agents, even in patients with advanced chronic kidney disease or those on dialysis. The panel concludes that the use of iodinated contrast media or group II gadolinium-based contrast agents should not be postponed in chronic kidney disease patients when clinically significant imaging studies are required.

2 December 2024 in Journal of the Formosan Medical Association
Verified
Journal Article
Open access
YCYu-Ching Chang
Yu-Ching Chang
LYLo-Chia Yeh
Lo-Chia Yeh
TLTing-Tse Lin
Ting-Tse Lin
CHChing-Chang Huang
Ching-Chang Huang
CHChi-Sheng Hung
Chi-Sheng Hung
YLYen-Hung Lin
Yen-Hung Lin
Clinical and experimental evidence have demonstrated the protective benefits of colchicine in acute myocardial infarction (AMI) through its potential anti-inflammatory effect. However, investigations on the Asian population are limited. This retrospective longitudinal cohort study used electronic medical records from a tertiary medical center in Taiwan. Patients with their first AMI from the emergency department between 2010 and 2020 were included. The outcomes included all-cause death, hospitalization for heart failure, stroke, and emergency admission for angina. Propensity-score matching (PSM, 5 to 1) and Cox's proportional hazards regression model were used to estimate hazard ratios (HRs). A total of 2841 patients with their first admission for AMI were identified, of which 176 (6.2%) received colchicine and 2665 (93.8%) did not. After a median follow-up of 21.4 months, the incidence of all-cause death was significantly reduced in the colchicine group (HR, 0.560; 95% confidence interval [CI], 0.361-0.862; P = 0.008), driven by the significant risk reduction of cardiovascular death (HR, 0.291; 95% CI, 0.142-0.613; P = 0.001). There was no significant difference of other outcomes. After PSM, the protective effect remained in the colchicine group compared with non-users (HR, 0.331; 95% CI, 0.162-0.690; P = 0.003). The relationship between endpoints and various time-to-treatment initiation showed a significant reduction in the risk of all-cause death for whom colchicine was initiated < Day 3 compared with placebo. Low-dose colchicine led to a significantly lower risk of cardiovascular death than non-users among patients with a recent myocardial infarction. They benefit from early, in-hospital initiation of colchicine after AMI.

1 May 2026 in Hypertension
Verified
Journal Article
Closed access
YCYu-Ching Chang
Yu-Ching Chang
CHChi-Sheng Hung
Chi-Sheng Hung
ZCZhengWei Chen
ZhengWei Chen
YCYi-Yao Chang
Yi-Yao Chang
CCChin-Chen Chang
Chin-Chen Chang
YLYen-Hung Lin
Yen-Hung Lin
BACKGROUND: Sex differences influence cardiovascular risk assessment and management; however, their role in aldosterone-mediated cardiac remodeling in primary aldosteronism remains incompletely understood. METHODS: We conducted a retrospective study of 547 patients with primary aldosteronism, including 249 men and 298 women. Clinical and echocardiographic data were collected at baseline and 1 year following aldosterone-targeted therapies. RESULTS: The mean age was 53.8 years in men and 54.6 years in women. At baseline, men had a higher left ventricular mass index (LVMI), whereas women had a higher prevalence of left ventricular (LV) hypertrophy and worse diastolic function, as indicated by a higher ratio of early diastolic transmitral to mitral annular velocity (E/e′) and left atrial volume index. In multivariable analyses, plasma aldosterone concentration (PAC) was associated with baseline LVMI in both sexes. Associations between PAC and baseline diastolic indices, including E/e′ and left atrial volume index, were observed in men but not in women in sex-stratified models. However, formal interaction testing did not demonstrate significant sex-by- PAC interactions for left atrial volume index, E/e′, or LAVI. After 1 year of treatment, LVMI reduction was comparable between sexes. Improvement in E/e′ was significantly less pronounced in women. LAVI decreased significantly in men but not in women, although between-sex differences in change were not statistically significant. CONCLUSIONS: Sex-specific differences in cardiac remodeling and diastolic function were observed in patients with primary aldosteronism. Despite lower baseline LVMI, women exhibited a more adverse cardiac phenotype, with a higher prevalence of left ventricular hypertrophy and worse diastolic function. Following aldosterone-targeted therapies, structural regression was similar between sexes, whereas diastolic function improved to a lesser extent in women.

29 June 2026 in SSRN Electronic Journal
Verified
Preprint
Open access
YCYu-Ching Chang
Yu-Ching Chang
CHChi-Sheng Hung
Chi-Sheng Hung
UCUei-Lin Chen
Uei-Lin Chen
YHYi-Hsin Hung
Yi-Hsin Hung
ZCZhengWei Chen
ZhengWei Chen
YLYen-Hung Lin
Yen-Hung Lin
Background: The cardio-kidney-metabolic (CKM) framework has been proposed as an integrated staging system for cardiometabolic risk. However, whether progression across CKM stages confers incremental mortality risk among individuals initially free of CKM abnormalities remains unclear.Methods: We conducted a prospective cohort study including 58,317 adults classified as CKM stage 0 at baseline who underwent at least two standardized health examinations between 1997 and 2016. CKM stage was reassessed at the last examination and categorized as stage 0, 1, 2, or 3–4. Participants were followed from the last examination through December 31, 2022 for mortality outcomes.Results: During a median follow-up of 12.9 years, progression across CKM stages was associated with a stepwise increase in mortality risk. Compared with individuals who remained at CKM stage 0, adjusted hazard ratios (aHRs) for all-cause mortality were 1.15 (95% confidence interval [CI], 1.00–1.31) for stage 1, 1.19 (95% CI, 1.04–1.37) for stage 2, and 1.65 (95% CI, 1.29–2.12) for stage 3–4 (P for trend <0.001). A similar graded association was observed for cardiovascular mortality (P for trend <0.001), with the highest risk in stage 3–4 (aHR, 3.15; 95% CI, 1.73–5.74). Notably, progression to early CKM stages (stage 1–2) was associated with increased mortality risk.Conclusion: Among adults initially classified as metabolically healthy at baseline, progression across CKM stages is associated with a graded increase in all-cause and cardiovascular mortality. These findings support CKM stage transition as a dynamic marker of risk and highlight the importance of preventing early cardiometabolic deterioration.

29 June 2026 in medRxiv
Verified
Preprint
Open access
CTCheng-Hsuan Tsai
Cheng-Hsuan Tsai
YCYu-Ching Chang
Yu-Ching Chang
CCChin-Chen Chang
Chin-Chen Chang
WWWan-Chen Wu
Wan-Chen Wu
YCYi-Yao Chang
Yi-Yao Chang
YLYen-Hung Lin
Yen-Hung Lin
Background: The fibrosis-4 index (FIB-4) is a simple noninvasive marker originally developed to assess liver fibrosis risk. Accumulating evidence suggests that FIB-4 is associated with adverse cardiovascular outcomes, but its prognostic relevance in patients with primary aldosteronism (PA) remains unclear. Methods: In this retrospective multicenter cohort study, patients with PA were stratified into low, intermediate, and high FIB-4 groups using established cutoffs: 2.67. Outcomes included all-cause mortality, ischemic stroke, hemorrhagic stroke, acute myocardial infarction, and major adverse cardiovascular events (MACE). Multivariable Cox proportional hazards models were used to estimate hazard ratios (HRs) across FIB-4 categories. Results: Among 2,467 patients with PA, 1,215 (49.3%) had FIB-4 2.67. Patients with higher FIB-4 were older and had lower body mass index, worse renal function, lower potassium, and a higher comorbidity burden. During follow-up, all-cause mortality increased across FIB-4 categories, from 13.9% in the low FIB-4 group to 58.1% in the high FIB-4 group. After multivariable adjustment, FIB-4 >2.67 was associated with higher risks of all-cause mortality (adjusted HR, 1.98; 95% CI, 1.54–2.54) and MACE (adjusted HR, 1.78; 95% CI, 1.44–2.20), compared with FIB-4 <1.3. Adjusted linear regression analyses showed that higher FIB-4 was significantly associated with lower renin and higher aldosterone-to-renin ratio. Conclusions: In patients with PA, elevated FIB-4 identified a high-risk subgroup with increased all-cause mortality and MACE. FIB-4 may serve as a simple, noninvasive tool for prognostic stratification in patients with PA. Novelty and Relevance: What Is New?: In this retrospective multicenter cohort of patients with primary aldosteronism, elevated FIB-4 identified a high-risk subgroup with increased all-cause mortality and MACE. FIB-4 was associated with PA-related biochemical markers, including plasma renin activity and the aldosterone-to-renin ratio, suggesting a link between FIB-4 and renin suppression in PA. This is the first study to evaluate the prognostic significance of FIB-4 in patients with PA and to examine its relationship with PA-related biochemical features. What Is Relevant?: PA is clinically heterogeneous, and conventional biochemical markers may not fully capture the cumulative multisystem risk burden in high-risk patients. FIB-4 is a simple, noninvasive, and routinely available index that may complement current risk stratification in PA by integrating biochemical, hepatic-metabolic, renal, and comorbidity-related information. Clinical Implications?: Incorporating FIB-4 into PA assessment may help identify patients who warrant more comprehensive evaluation of cardiovascular, renal, hepatic, and metabolic risk. Elevated FIB-4 may support closer clinical follow-up and more intensive risk-factor optimization in high-risk patients with PA.